Guggenheim Capital LLC Reduces Position in DENTSPLY SIRONA Inc (XRAY)

Guggenheim Capital LLC lowered its holdings in shares of DENTSPLY SIRONA Inc (NASDAQ:XRAY) by 1.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 715,814 shares of the medical instruments supplier’s stock after selling 9,568 shares during the period. Guggenheim Capital LLC owned approximately 0.31% of DENTSPLY SIRONA worth $47,123,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of XRAY. NuWave Investment Management LLC bought a new stake in DENTSPLY SIRONA during the fourth quarter worth about $121,000. First Interstate Bank bought a new stake in DENTSPLY SIRONA during the third quarter worth about $164,000. Focused Wealth Management Inc boosted its stake in DENTSPLY SIRONA by 79.2% during the fourth quarter. Focused Wealth Management Inc now owns 2,600 shares of the medical instruments supplier’s stock worth $171,000 after acquiring an additional 1,149 shares in the last quarter. Stock Yards Bank & Trust Co. bought a new stake in DENTSPLY SIRONA during the fourth quarter worth about $203,000. Finally, Capital One National Association bought a new stake in DENTSPLY SIRONA during the fourth quarter worth about $204,000. 96.80% of the stock is currently owned by institutional investors and hedge funds.

DENTSPLY SIRONA Inc (NASDAQ:XRAY) opened at $56.33 on Friday. The company has a current ratio of 2.12, a quick ratio of 1.46 and a debt-to-equity ratio of 0.24. DENTSPLY SIRONA Inc has a twelve month low of $52.53 and a twelve month high of $68.98. The firm has a market cap of $12,800.00, a P/E ratio of -8.42, a PEG ratio of 2.48 and a beta of 1.20.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings data on Thursday, March 1st. The medical instruments supplier reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.81 by $0.01. DENTSPLY SIRONA had a negative net margin of 39.39% and a positive return on equity of 8.35%. The firm had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.06 billion. During the same period in the previous year, the company earned $0.67 earnings per share. The firm’s quarterly revenue was up 9.5% on a year-over-year basis. analysts anticipate that DENTSPLY SIRONA Inc will post 2.75 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 13th. Stockholders of record on Thursday, March 29th will be issued a dividend of $0.0875 per share. The ex-dividend date of this dividend is Wednesday, March 28th. This represents a $0.35 annualized dividend and a dividend yield of 0.62%. DENTSPLY SIRONA’s payout ratio is -5.23%.

In other news, Director Eric Brandt sold 6,409 shares of the business’s stock in a transaction that occurred on Monday, January 8th. The shares were sold at an average price of $68.04, for a total transaction of $436,068.36. Following the completion of the transaction, the director now directly owns 12,073 shares of the company’s stock, valued at $821,446.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.99% of the stock is owned by insiders.

Several research firms recently commented on XRAY. HC Wainwright set a $63.00 price objective on shares of DENTSPLY SIRONA and gave the stock a “hold” rating in a research note on Monday, March 5th. Barclays assumed coverage on shares of DENTSPLY SIRONA in a research note on Thursday, March 8th. They set an “equal weight” rating and a $62.00 price objective on the stock. Barrington Research reaffirmed an “outperform” rating and issued a $70.00 target price (down from $73.00) on shares of DENTSPLY SIRONA in a report on Monday, March 5th. JPMorgan Chase & Co. decreased their target price on shares of DENTSPLY SIRONA from $75.00 to $70.00 and set an “overweight” rating for the company in a report on Monday, March 5th. Finally, BidaskClub cut shares of DENTSPLY SIRONA from a “sell” rating to a “strong sell” rating in a report on Wednesday, February 28th. Three research analysts have rated the stock with a sell rating, four have issued a hold rating and nine have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $67.43.

TRADEMARK VIOLATION WARNING: This article was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at


DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Institutional Ownership by Quarter for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with's FREE daily email newsletter.

Leave a Reply